HRHarrow Health, Inc. HROW · NASDAQ
$27.68 +1.47% (+$0.40)
- Market cap
- $1.04B
- Enterprise value
- $1.25B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.8x
- P/FCF
- 182.5x
- EV/EBITDA
- 279.8x
- ROIC
- 2.0%
- Gross margin
- 73.3%
- Net margin
- -13.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 48.4x
- Beta
- 0.24
- Free float
- 77.2%
About the company
Harrow Health, Inc. is a pharmaceutical company primarily focused on providing affordable and innovative drugs and healthcare products. The company specializes in the development and commercialization of pharmaceuticals and medical devices in the fields of ophthalmology, dermatology, and neurology. Their portfolio includes a wide range of therapeutic products, including generics, branded drugs, and medical devices, aimed at treating various health conditions and diseases. Harrow Health, Inc. focuses on providing affordable and quality medications for patients and strengthening its position in the pharmaceuticals and healthcare products market.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mark L. Baum
Employees
373
Headquarters
Nashville
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number